Wire · opportunities
When the Consent Form Is the Catastrophe: What Alembic's FDA Warning Letter Means for Your Site
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 July 2026 · Fusion42 review
Alembic Pharmaceuticals received an FDA warning letter for obtaining informed consent after study procedures had begun at its bioequivalence facility in India. The deficiency, exposed during a BIMO inspection in March 2025, raises questions about data integrity in any ANDA submissions relying on that site's bioequivalence data.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you run or supply bioequivalence sites, an FDA warning letter for consent sequencing just made that procedural shortcut a data-integrity finding—one that can sink an ANDA filing. Your monitoring budget and consent workflow need to be redesigned around timestamp audit trails, not cohort throughput.
◆ Coverage
1 source · 23 Jul 2026
◆ Related on Wire
◆ Topics